Pay in 4 interest-free payments of $6.73 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
10.1186/s43162-020-00026-9 36 GersteinH
American Diabetes Assocation, 85th Scientific Sessions
LY3298176 has the potential to deliver clinically meaningful improvement in glycaemic control and body weight
Educational materials covering laboratory handling, compound stability, and regulatory considerations for research environments
In Lyme disease, these batteries often run dangerously low
US$ 26.03
US$ 27.96
US$ 23.58
US$ 26.34
US$ 23.01
US$ 25.16
US$ 28.27
US$ 28.79
![Yzma - Choosy Customer (V.1) - Attack of the Vine! (Common) [13ATV-110] Language:English](https://cdn.shopify.com/s/files/1/0970/9309/1669/files/897304.jpg?v=1784824525)
![Luxury Suite - Commander: Marvel Super Heroes (Rare) [MSC-252] Language:English](https://cdn.shopify.com/s/files/1/0970/9309/1669/files/892463.jpg?v=1781610810)
